J
Juventas Therapeutics
Clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases
About Juventas Therapeutics
Juventas Therapeutics is a private, clinical-stage biotechnology company focused on developing innovative non-viral gene therapies. These therapies are designed to activate the body's natural repair mechanisms, specifically through the use of stromal cell-derived factor 1 (SDF-1), a signaling protein that recruits stem cells to promote tissue repair. The company's flagship product candidate, JVS-100, leverages this approach to address a broad range of disease states.
Juventas operates in the regenerative medicine market, targeting conditions that require tissue repair and regeneration. Its clients primarily include healthcare providers and patients suffering from diseases that can benefit from advanced gene therapy solutions.
The business model is centered around the development and clinical testing of its proprietary therapies, with the aim of eventually bringing these treatments to market. Revenue generation will likely come from the commercialization of its therapies, either through direct sales or partnerships with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Johnstown, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 58.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2021 | $63M | $252M | Undisclosed | — |
| SERIES BOther financing | May 2015 | $14M | $54M | Green Cross · POSCO Venture Capital | — |
Growth signals
Latest recorded traffic for Juventas Therapeutics is 30 monthly website visits, down 94.1% over the last three months. Juventas Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
JumpStart
Series A9 investors entered at this stage
- TPTriathlon Medical Venture Partners
- EPEarly Stage Partners
New Science Ventures
Venture Investors Health Fund
Takeda Ventures- RPReservoir Venture Partners
North Coast Ventures
Green Cross
POSCO Venture Capital
Other known investors1 additional known investor
Cleveland Clinic
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Juventas Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Juventas Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.